For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Harvard Bioscience Inc (NASDAQ: HBIO) closed at $0.38 down -5.18% from its previous closing price of $0.4. In other words, the price has decreased by -$5.18 from its previous closing price. On the day, 1.39 million shares were traded. HBIO stock price reached its highest trading level at $0.41 during the session, while it also had its lowest trading level at $0.3779.
Ratios:
For a deeper understanding of Harvard Bioscience Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.27 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.83. For the most recent quarter (mrq), Quick Ratio is recorded 0.41 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 2.75 whereas as Long-Term Debt/Eq ratio is at 0.45.
On March 10, 2023, The Benchmark Company Upgraded its rating to Buy which previously was Speculative Buy and also upped its target price recommendation from $3 to $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HBIO now has a Market Capitalization of 16890684 and an Enterprise Value of 52806684. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.19 while its Price-to-Book (P/B) ratio in mrq is 1.07. Its current Enterprise Value per Revenue stands at 0.595 whereas that against EBITDA is 14.926.
Stock Price History:
The Beta on a monthly basis for HBIO is 1.59, which has changed by -0.83966243 over the last 52 weeks, in comparison to a change of 0.13837254 over the same period for the S&P500. Over the past 52 weeks, HBIO has reached a high of $2.82, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is -18.40%, while the 200-Day Moving Average is calculated to be -46.11%.
Shares Statistics:
For the past three months, HBIO has traded an average of 837.36K shares per day and 701100 over the past ten days. A total of 44.53M shares are outstanding, with a floating share count of 37.92M. Insiders hold about 14.85% of the company’s shares, while institutions hold 43.91% stake in the company. Shares short for HBIO as of 1759190400 were 681364 with a Short Ratio of 0.81, compared to 1756425600 on 757327. Therefore, it implies a Short% of Shares Outstanding of 681364 and a Short% of Float of 1.6500000000000001.
Earnings Estimates
Investors are keenly observing as 2.0 analysts analyze and rate. The current performance of Harvard Bioscience Inc (HBIO) in the stock market.The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.04.
Analysts are recommending an EPS of between $0.03 and $0.02 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is $0.12, with 2.0 analysts recommending between $0.15 and $0.1.
Revenue Estimates
A total of 2 analysts believe the company’s revenue will be $20M this quarter.It ranges from a high estimate of $21M to a low estimate of $19M. As of. The current estimate, Harvard Bioscience Inc’s year-ago sales were $21.97MFor the next quarter, 2 analysts are estimating revenue of $23.1M. There is a high estimate of $23.4M for the next quarter, whereas the lowest estimate is $22.8M.
A total of 2 analysts have provided revenue estimates for HBIO’s current fiscal year. The highest revenue estimate was $86.6M, while the lowest revenue estimate was $84M, resulting in an average revenue estimate of $85.3M. In the same quarter a year ago, actual revenue was $94.14MBased on 2 analysts’ estimates, the company’s revenue will be $91.5M in the next fiscal year. The high estimate is $95.6M and the low estimate is $87.4M.
